Activest Wealth Management Takes $36,000 Position in Stryker Co. (NYSE:SYK)

Activest Wealth Management purchased a new position in shares of Stryker Co. (NYSE:SYK) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 101 shares of the medical technology company’s stock, valued at approximately $36,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Newbridge Financial Services Group Inc. acquired a new position in Stryker in the fourth quarter worth $52,000. Kestra Private Wealth Services LLC raised its holdings in shares of Stryker by 6.8% in the fourth quarter. Kestra Private Wealth Services LLC now owns 19,064 shares of the medical technology company’s stock valued at $6,864,000 after buying an additional 1,206 shares during the last quarter. Howland Capital Management LLC lifted its position in Stryker by 9.5% during the 4th quarter. Howland Capital Management LLC now owns 87,461 shares of the medical technology company’s stock worth $31,564,000 after buying an additional 7,611 shares in the last quarter. Birch Hill Investment Advisors LLC grew its holdings in Stryker by 29.5% during the 4th quarter. Birch Hill Investment Advisors LLC now owns 795 shares of the medical technology company’s stock worth $286,000 after acquiring an additional 181 shares during the last quarter. Finally, Entropy Technologies LP acquired a new stake in Stryker in the 4th quarter valued at about $236,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 1.2 %

Stryker stock opened at $391.42 on Monday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a 50 day moving average of $377.23 and a 200-day moving average of $364.97. The stock has a market capitalization of $149.22 billion, a PE ratio of 50.44, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business posted $3.46 EPS. On average, equities research analysts anticipate that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is presently 43.30%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SYK. Robert W. Baird increased their price target on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research report on Wednesday, January 29th. Royal Bank of Canada boosted their target price on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Finally, The Goldman Sachs Group boosted their price objective on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $419.37.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.